Related Experiment Video

Updated: Oct 14, 2026

Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

2.4K

Antifungal activity of Rhopalurus crassicauda venom against Candida spp

Umberto Zottich1, Isadora Sousa de Oliveira2, Isabela Gobbo Fereira2

  • 1Medical School, Federal University of Roraima, Boa Vista, Roraima, Brazil.

Toxicon: X
|March 29, 2022
PubMed

Insights

Scorpion venom and its major toxin, Rc1, show promising antifungal effects against Candida infections. This research highlights potential new treatments for challenging fungal diseases.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Mycology

Background:

  • Fungal infections, particularly those caused by *Candida* species, pose a significant global health challenge.
  • Current antifungal therapies are limited, driving the need for novel therapeutic agents.
  • Scorpions are a rich source of bioactive peptides with diverse pharmacological properties.

Purpose of the Study:

  • To investigate the antifungal activity of venom, mucus, and the major toxin (Rc1) from the scorpion *Rhopalurus crassicauda*.
  • To evaluate the potential of these natural compounds as lead compounds for developing new antifungal drugs.
  • To explore novel therapeutic strategies against *Candida* infections.

Main Methods:

  • Extraction and isolation of venom, mucus, and Rc1 from *Rhopalurus crassicauda*.
  • In vitro testing of antifungal activity against *Candida* species.
  • Biochemical characterization of the major toxin Rc1.

Main Results:

  • The venom, mucus, and purified Rc1 toxin demonstrated significant antifungal effects against *Candida*.
  • Rc1 exhibited potent inhibitory activity, suggesting it as a key bioactive component.
  • Preliminary data indicate Rc1's potential as a novel antifungal therapeutic.

Conclusions:

  • The *Rhopalurus crassicauda* scorpion yields compounds with notable antifungal properties.
  • Rc1 toxin shows promise as a novel therapeutic candidate for treating *Candida* infections.
  • Further investigation into Rc1 could lead to the development of effective antifungal drugs.
Keywords:
AntifungalCandida albicansCandida parapsilosisRhopalurus crassicaudascorpion Toxin

More Related Videos

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms06:50

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

3.2K
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis06:39

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

1.1K

Related Concept Videos

Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...